Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $5 million (excluding any proceeds that may be received upon the ...

Alterity Therapeutics ATHE shares rose 97.2% to $5.74 during Thursday's pre-market session. The company's market cap stands at $50.1 million. NanoVibronix NAOV shares ros ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his ...

根据 InvestingPro 的数据，Processa Pharmaceuticals, Inc. (NASDAQ: PCSA )的首席执行官George ...

已保存。查看收藏列表。 Processa Pharmaceuticals, Inc.（纳斯达克股票代码：PCSA）的首席商务和战略官Patrick ...

Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...

Processa Pharmaceuticals Inc. (PCSA) stock has tumbled to a 52-week low, touching down at $0.65, with InvestingPro data ...

Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition ...